Printer Friendly

Eisai Establishes European Strategic Business Hub in the U.K.

Tokyo, Japan, Jan 25, 2006 - (JCN Newswire) - Eisai Europe Ltd. (Headquarter: London, President: Yutaka Tsuchiya), a regional headquarter in Europe and a subsidiary of Eisai Co., Ltd. (Headquarter: Tokyo, President and CEO: Haruo Naito) concluded the Heads of Terms with Arlington Securities Ltd. in the U.K. on land sales and the development to establish a strategic business hub in Europe. Eisai will consolidate the internal functions including discovery research, clinical development, production, sales and headquarters operations in Europe in this place to establish a strategic business hub which will be a center of business activities across Europe.

The site Eisai concluded the Heads of Terms this time is about 14.6 acres of land in the Hatfield Business Park located in the northern London and a new manufacturing subsidiary with plants will be built here. The construction will be started in 2006 and Eisai Europe Ltd., an existing regional headquarter in Europe, and Eisai Ltd., a subsidiary of clinical research and sales, will be sequentially relocated to this site. Further adding a discovery research function to the site to expand and strengthen Eisai London Research Laboratories, Ltd., a subsidiary of discovery research located at the University of London (UCL), the first production and research activities for drug discovery will be started in 2008. Eisai assumes that total invested amount including cost for purchasing the land will be approx. 15 billion yen. Furthermore, establishment of the hub will create more than 500 jobs in total including new employment of 300 employees in the Hatfield Business Park.

Eisai considers European regions very important because they have not only high potential for growth in the pharmaceutical market but the system of advanced scientific technology and clinical development. Above all, the U.K. has an innovative history in the field of life science and it is a cluster for the pharmaceutical industry. Accordingly, Eisai decided that the U.K. would be the best place to establish a strategic business hub. Eisai has already discovered a new chemical compound which is under development as a drug for neurodegenerative diseases including Parkinson's disease, epilepsy and multiple sclerosis in the research laboratory at the University of London (UCL) established in 1990. Eisai looks for a discovery leading to a further breakthrough by establishing a new strategic business hub in this region which is a cluster for the pharmaceutical and biotechnology industries in the U.K.

The establishment of a strategic business hub in Europe this time will enable us to create a seamless value chain in which the internal functions including discovery research, clinical development R&D, production, sales, and the management and provision of information used in safety monitoring are closely coordinated with each other and quick and stable provision of high quality products in accordance with patient needs with useful information will be possible. With this seamless value chain, Eisai will work on further improvement of the efficiency, productivity and quality of our products.

Eisai has already set up sales subsidiaries in major regions of Europe including the U.K., Germany, France, Spain, Italy, Switzerland and Sweden to improve the sales structure of our pharmaceutical products. Eisai will strive to accelerate the expansion of our business with a comprehensive view of all over the Europe, enhance satisfaction of patients and contribute to the improvement of benefits of more patients in Europe in the future.

About Eisai Co., Ltd.

Eisai Co., Ltd. (TSE: 4523)(OTC: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit

Source: Eisai Co., Ltd.

Eisai Co., Ltd.
Corporate Communications Department

Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Geographic Code:9JAPA
Date:Jan 26, 2006
Previous Article:IB Daiwa Announces Test Results from Kami Gas Field - Tests Flow Rates Exceed Pre-drilling Expectations.
Next Article:Honda Sets All-Time Annual Records for Overseas and Worldwide Automobile Production.

Related Articles
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.
Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Lawsuit Against Generic Drug Manufacturers Dismissed.
Sanko Junyaku, Eisai and Fujirebio Sign Joint Research Agreement for Development of New KL-6 Test Kit.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Eisai Establishes New Manufacturing Subsidiary in United Kingdom.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |